@article {10825, title = {Ocular Manifestations of Paediatric Inflammatory Bowel Disease: A Systematic Review and Meta-analysis.}, journal = {J Crohns Colitis}, volume = {12}, year = {2018}, month = {2018 Jun 28}, pages = {870-879}, abstract = {

Background and Aims: Ocular extraintestinal manifestations [O-EIMs] are known complications of Crohn{\textquoteright}s disease [CD], ulcerative colitis [UC], and inflammatory bowel disease unclassified [IBD-U]. However, data on their prevalence in children are scarce and there are no clear recommendations on what follow-up should be offered. We aimed to review available data on O-EIMs in children.

Methods: In January 2018, we performed a systematic review of published English literature using PubMed and EMBASE databases and disease-specific queries.

Results: Fifteen studies [7467 patients] reported data on O-EIMs prevalence in children. Overall prevalence of O-EIMs was 0.62-1.82\%. Uveitis was the most common O-EIM. Meta-analysis showed that children with CD are at increased risk of O-EIMs as compared with children with UC and IBD-U (odds ratio [OR] 2.70, 95\% confidence interval [CI] 1.51-4.83). Five studies [357 patients] reported data on ophthalmological screening in asymptomatic children: mild asymptomatic uveitis was identified in a variable proportion of patients [1.06-23.1\%], more frequently in male patients with CD and colonic involvement. No evidence of ocular complications from untreated uveitis was detected. A total of 23 case reports [24 patients] were identified.

Conclusions: Data on O-EIMs in children are scarce. Prevalence of O-EIMs is lower than in adults but may be underestimated because of the possibility of asymptomatic uveitis; however, the long-term significance of this condition is unknown. Children with CD may be at increased risk of O-EIMs. No recommendations on routine ophthalmological examination can be made, but a low threshold for ophthalmological referral should be maintained. Larger studies in paediatric IBD populations are needed.

}, keywords = {Adolescent, Cataract, Child, Child, Preschool, Colitis, Ulcerative, Crohn Disease, Eye Diseases, Humans, Prevalence, Uveitis}, issn = {1876-4479}, doi = {10.1093/ecco-jcc/jjy029}, author = {Ottaviano, Giorgio and Salvatore, Silvia and Salvatoni, Alessandro and Martelossi, Stefano and Ventura, Alessandro and Naviglio, Samuele} } @article {10826, title = {Off-label drugs use in pediatric palliative care.}, journal = {Ital J Pediatr}, volume = {44}, year = {2018}, month = {2018 Nov 29}, pages = {144}, abstract = {

BACKGROUND: Paediatric palliative care (PPC) aim to ensure the control of symptoms and the best possible quality of life for patients whose underlying disease, characterized by an unstoppable evolution and negative prognosis, no longer responds to specific treatments. The scientific evidence in this context are very deficient and, in order to obtain welfare objectives consistent with the situation, in the overwhelming majority of cases the prescription of drugs is off-label for indication of use and/or for age and/or for way of administration and/or formulation. The Agenzia Italiana del Farmaco - AIFA and the Italian Society of Palliative Care (Societ{\`a} Italiana di Cure Palliative - SICP), under a dedicated working group, wrote a document that collects the scientific evidence available to support the off-label use of medicines more frequently used in PPC. The goal is to certify the consolidated off-label use of these drugs and propose their use under the Law 648/96, in the absence of data from its pivotal clinical trials. Aim of the commentary is to report the conditions for this important work and to present the 10 drugs, usually used off-label in PPC and in pain therapy, now included in Law 648/96.

CONCLUSION: This work is deemed essential to resolve, at least in part, the lack of availability of medicines researched and approved.

}, issn = {1824-7288}, doi = {10.1186/s13052-018-0584-8}, author = {De Zen, Lucia and Marchetti, Federico and Barbi, Egidio and Benini, Franca} } @article {10827, title = {Orthopaedic challenges for mucopolysaccharidoses.}, journal = {Ital J Pediatr}, volume = {44}, year = {2018}, month = {2018 Nov 16}, pages = {123}, abstract = {

Mucopolysaccharidoses (MPS) are a group of diseases characterized by abnormal accumulation of glycosaminoglycans (GAGs). Although there are differences among the various disease types, the osteoarticular system is always involved. The aim of the present study was to establish a framework for MPS-related orthopaedic manifestations and for their treatment. The authors, affiliated to three different Italian Orthopaedic Centres, report data taken from the literature reviewed in light of their accumulated professional experience. Bone alterations make up what is known as dysostosis multiplex, involving the trunk and limbs and with typical radiological findings. Joints are affected by pathological tissue infiltrations. The cervical spinal cord is involved, with stenosis and cervical and occipitocervical instability. In MPS there is a much higher incidence of scoliosis compared with healthy subjects without any particular distinctive feature. Kyphosis of the spine is more frequent and also more severe because of its possible neurological complications, and it is localized at the thoracolumbar level with a malformed vertebra at the top of the deformity. Evolving forms, and those associated with neurological damage, require anteroposterior spine fusion. The hip is invariably involved, with dysplasia affecting the femoral neck (coxa valga), the femoral epiphysis (loss of sphericity, osteonecrosis), and the femoral acetabulum which is flared. All these features explain the tendency to progressive hip migration. Genu valgum is often found (a deviation of the physiological axis with an obtuse angle opening laterally). This deformity is often localized at the proximal tibial metaphysis; it causes functional limitations and leads to an irregular erosion of the articular cartilage. In young patients who still have the growth plate, it is possible to execute a medial hemiepiphysiodesis, a temporary inhibition of cartilage growth, with progressive axis correction. In this paper, the characterisation of clinical features and the review of treatments are divided into separate sections based on the part of the body involved. The conclusions of each section are presented as a summary. One section discusses the high risk of anaesthesia-related complications requiring the collaboration of specifically trained personnel.

}, keywords = {Bone Diseases, Humans, Mucopolysaccharidoses, Orthopedic Procedures}, issn = {1824-7288}, doi = {10.1186/s13052-018-0557-y}, author = {Borgo, Andrea and Cossio, Andrea and Gallone, Denise and Vittoria, Francesca and Carbone, Marco} } @article {10548, title = {Ocular Involvement in Children with Inflammatory Bowel Disease.}, journal = {Inflamm Bowel Dis}, volume = {23}, year = {2017}, month = {2017 06}, pages = {986-990}, abstract = {

BACKGROUND: Data on ocular manifestations of inflammatory bowel disease (IBD) in children are limited. Some authors have reported a high prevalence of asymptomatic uveitis, yet the significance of these observations is unknown and there are no recommendations on which ophthalmologic follow-up should be offered.

METHODS: Children with IBD seen at a single referral center for pediatric gastroenterology were offered ophthalmologic evaluation as part of routine care for their disease. Ophthalmologic evaluation included review of ocular history as well as slit-lamp and fundoscopic examination. Medical records were also reviewed for previous ophthalmologic diagnoses or complaints.

RESULTS: Data from 94 children were included (52 boys; median age 13.4 yr). Forty-six patients had a diagnosis of Crohn{\textquoteright}s disease, 46 ulcerative colitis, and 2 IBD unclassified. Intestinal disease was in clinical remission in 70\% of the patients; fecal calprotectin was elevated in 64\%. One patient with Crohn{\textquoteright}s disease had a previous diagnosis of clinically manifest uveitis (overall uveitis prevalence: 1.06\%; incidence rate: 0.3 per 100 patient-years). This patient was also the only one who was found to have asymptomatic uveitis at slit-lamp examination. A second patient had posterior subcapsular cataract associated with corticosteroid treatment. No signs of intraocular complications from previous unrecognized uveitis were observed in any patient.

CONCLUSIONS: Children with IBD may have asymptomatic uveitis, yet its prevalence seems lower than previously reported, and it was not found in children without a previous diagnosis of clinically manifest uveitis. No ocular complications from prior unrecognized uveitis were observed.

}, keywords = {Adolescent, Child, Child, Preschool, Feces, Female, Humans, Inflammatory Bowel Diseases, Italy, Leukocyte L1 Antigen Complex, Male, Remission Induction, Uveitis}, issn = {1536-4844}, doi = {10.1097/MIB.0000000000001079}, author = {Naviglio, Samuele and Parentin, Fulvio and Nider, Silvia and Rassu, Nicol{\`o} and Martelossi, Stefano and Ventura, Alessandro} } @article {10563, title = {Outcome of childhood-onset full-house nephropathy.}, journal = {Nephrol Dial Transplant}, volume = {32}, year = {2017}, month = {2017 Jul 01}, pages = {1194-1204}, abstract = {

Background: Patients with full-house nephropathy (FHN) present renal lesions that are indistinguishable from those of lupus nephritis (LN) but lack the systemic features necessary to meet diagnostic criteria for systemic lupus erithematosus (SLE). Some have been reported to develop a delayed SLE with time. The clinical outcome of children having FHN without SLE has never been reported.

Methods: Children with biopsy-proven FHN were selected after excluding SLE cases by the absence of America College of Rheumatology criteria. The proportion of patients with complete (proteinuria <0.5 g/day) or partial remission (proteinuria <=50\% from baseline), relapse (estimated glomerular filtration rate <25\% and/or proteinuria >=50\% from baseline) and progression to Stage III chronic kidney disease (CKD) was described according to age and gender groups with the Kaplan-Meier curve and compared with the Log-rank test. Entity of treatment was summarized by a score at induction (0-6 months) and maintenance (6-18 months). Cox-regression model was performed to test predictors of remission, relapse and progression to CKD.

Results: Among 42 patients (28 pre-pubertal) who met the inclusion criteria, 39 (92.9\%) achieved partial and 32 (76.2\%) complete remission of nephropathy over 2.78 and 7.51 months of follow-up. At 10 years, the probability of progressing to CKD was 4.8\%. Of those achieving remission, 18\% had a renal flare mainly within 4 years after remission. Pre-pubertal males achieved complete remission more frequently than other patients but often relapsed; pre-pubertal females were treated more aggressively. Cox-regression analysis did not find independent predictors of remission or relapse.

Conclusions: The outcome of the patients with FHN we investigated was encouraging. Recurrences are limited to the first 4 years following diagnosis, allowing progressive withdrawal of immunosuppression in patients achieving remission. Evaluation of risk factors for adverse outcome is necessary especially in pre-pubertal children.

}, keywords = {Adolescent, Age of Onset, Child, Disease Progression, Female, Glomerular Filtration Rate, Glomerulonephritis, Humans, Kidney Diseases, Lupus Erythematosus, Systemic, Lupus Nephritis, Male, Proteinuria, Recurrence, Remission Induction, Retrospective Studies, Risk Factors, Survival Rate}, issn = {1460-2385}, doi = {10.1093/ndt/gfw230}, author = {Ruggiero, Barbara and Vivarelli, Marina and Gianviti, Alessandra and Pecoraro, Carmine and Peruzzi, Licia and Benetti, Elisa and Ventura, Giovanna and Pennesi, Marco and Murer, Luisa and Coppo, Rosanna and Emma, Francesco} } @article {8072, title = {The one-step synthesis and surface functionalization of dumbbell-like gold-iron oxide nanoparticles: a chitosan-based nanotheranostic system.}, journal = {Chem Commun (Camb)}, volume = {52}, year = {2016}, month = {2016 Jan 7}, pages = {378-81}, abstract = {

The first one-step synthesis of dumbbell-like gold-iron oxide nanoparticles has been reported here. Surface functionalization with a biocompatible chitosan matrix allowed us to obtain a novel targetable diagnostic and therapeutic tool.

}, issn = {1364-548X}, doi = {10.1039/c5cc08275g}, author = {Kostevsek, Nina and Locatelli, Erica and Garrovo, Chiara and Arena, Francesca and Monaco, Ilaria and Nikolov, Ivaylo Petrov and Sturm, Saso and Zuzek Rozman, Kristina and Lorusso, Vito and Giustetto, Pierangela and Bardini, Paola and Biffi, Stefania and Comes Franchini, Mauro} } @article {8485, title = {Oral zinc provision in acute diarrhea.}, journal = {Curr Opin Clin Nutr Metab Care}, volume = {19}, year = {2016}, month = {2016 May}, pages = {239-43}, abstract = {

PURPOSE OF REVIEW: The clinical management of acute diarrhea is based on the use of oral rehydration salts and appropriate nutrition. In addition, the WHO and The United Nations Children{\textquoteright}s Fund recommend zinc supplementation for diarrhea in children below 5 years. This article aims at reviewing recent literature on the effects of oral zinc for treating acute diarrhea in children.

RECENT FINDINGS: Recent studies confirm that zinc supplementation has a benefit in children below 5 years with acute diarrhea in countries at medium or high risk of zinc deficiency. A few small trials have reported a benefit of zinc in children at low risk of zinc deficiency, with heterogeneity in results. No recent study has explored the effects of zinc in children younger than 6 months, and in this age group previous research refuted any benefit from zinc.

SUMMARY: Current literature supports the use of oral zinc in treating diarrhea in children older than 6 months, especially if at risk of zinc deficiency, such as children with poor diets exposed to recurrent gastrointestinal infections. More research is needed to confirm findings in children at low risk of zinc deficiency. Currently there is no evidence that zinc benefits children younger than 6 months.

}, issn = {1473-6519}, doi = {10.1097/MCO.0000000000000276}, author = {Lazzerini, Marzia} } @article {7735, title = {Ondasetron Is More Likely Than Ketamine to Cause Ventricular Tachycardia.}, journal = {Pediatr Emerg Care}, volume = {31}, year = {2015}, month = {2015 Aug}, pages = {e4}, keywords = {Anesthetics, Dissociative, Female, Humans, Ketamine, Tachycardia, Ventricular}, issn = {1535-1815}, doi = {10.1097/PEC.0000000000000521}, author = {Marzuillo, Pierluigi and Rabach, Ingrid and Barbi, Egidio} } @article {3594, title = {Is "option B+" also being adopted in pregnant women in high-income countries? Temporal trends from a national study in Italy.}, journal = {Clin Infect Dis}, volume = {60}, year = {2015}, month = {2015 Jan 1}, pages = {159-61}, keywords = {Anti-Retroviral Agents, Antiretroviral Therapy, Highly Active, Developed Countries, Female, HIV Infections, Humans, Infant, Newborn, Italy, Patient Acceptance of Health Care, Pregnancy, Pregnancy Complications, Infectious}, issn = {1537-6591}, doi = {10.1093/cid/ciu736}, author = {Floridia, Marco and Guaraldi, Giovanni and Ravizza, Marina and Tibaldi, Cecilia and Pinnetti, Carmela and Maccabruni, Anna and Molinari, Atim and Liuzzi, Giuseppina and Alberico, Salvatore and Meloni, Alessandra and Rizzi, Laura and Dalzero, Serena and Tamburrini, Enrica} } @article {7745, title = {Orofacial granulomatosis in children: think about Crohn{\textquoteright}s disease.}, journal = {Dig Liver Dis}, volume = {47}, year = {2015}, month = {2015 Apr}, pages = {338-41}, abstract = {

BACKGROUND: The term orofacial granulomatosis is conventionally used to describe patients with granulomatous lesions affecting the orofacial tissues, in absence of intestinal lesions. Lip swelling and facial swelling are the most common clinical signs. Despite the fact that histologically it is not distinguishable from Crohn{\textquoteright}s disease, and that both diseases have a chronic/recurrent course, the relationship between orofacial granulomatosis and Crohn{\textquoteright}s disease is still debated.

METHODS: Herein we present five cases of orofacial granulomatosis.

RESULTS: All patients presented concomitant Crohn{\textquoteright}s disease, supporting the hypothesis that orofacial granulomatosis and Crohn{\textquoteright}s disease may be one single disease. Thalidomide was effective in inducing remission of oral and intestinal symptoms in all five cases and could be considered a valid treatment opportunity for these patients.

CONCLUSIONS: Orofacial granulomatosis and Crohn{\textquoteright}s disease may be part of the same disease; both may respond to thalidomide.

}, keywords = {Adolescent, Biopsy, Child, Colonoscopy, Crohn Disease, Diagnosis, Differential, Female, Granulomatosis, Orofacial, Humans, Immunosuppressive Agents, Male, Thalidomide}, issn = {1878-3562}, doi = {10.1016/j.dld.2014.12.012}, author = {Lazzerini, Marzia and Martelossi, Stefano and Cont, Gabriele and Bersanini, Chiara and Ventura, Giovanna and Fontana, Massimo and Zuin, Giovanna and Ventura, Alessandro and Taddio, Andrea} } @article {3579, title = {Osteoprotegerin increases in metabolic syndrome and promotes adipose tissue proinflammatory changes.}, journal = {Mol Cell Endocrinol}, volume = {394}, year = {2014}, month = {2014 Aug 25}, pages = {13-20}, abstract = {

BACKGROUND: Inflammation is believed to link obesity to insulin resistance, as in the setting of metabolic syndrome (MetS). Osteoprotegerin (OPG) is a soluble protein that seems to exert proatherogenic and prodiabetogenic effects. This study aims at determining OPG levels in MetS and whether OPG might contribute to MetS development and progression.

METHODOLOGY/PRINCIPAL FINDINGS: Circulating OPG was measured in 46 patients with MetS and 63 controls, and was found significantly elevated in those with MetS. In addition, circulating and tissue OPG was significantly increased in high-fat diet (HFD) fed C57BL6 mice, which is one of the animal models for the study of MetS. To evaluate the consequences of OPG elevation, we delivered this protein to C57BL6 mice, finding that it promoted systemic and adipose tissue proinflammatory changes in association with metabolic abnormalities.

CONCLUSIONS/SIGNIFICANCE: These data suggest that OPG may trigger adipose tissue proinflammatory changes in MetS/HFD-induced obesity.

}, keywords = {Adipose Tissue, Adult, Animals, Blood Glucose, Body Mass Index, C-Reactive Protein, Case-Control Studies, Cholesterol, HDL, Cholesterol, LDL, Diet, High-Fat, Female, Humans, Inflammation, Insulin, Insulin Resistance, Male, Metabolic Syndrome X, Mice, Mice, Inbred C57BL, Middle Aged, Obesity, Osteoprotegerin, Triglycerides}, issn = {1872-8057}, doi = {10.1016/j.mce.2014.06.004}, author = {Bernardi, Stella and Fabris, Bruno and Thomas, Merlin and Toffoli, Barbara and Tikellis, Christos and Candido, Riccardo and Catena, Cristiana and Mulatero, Paolo and Barbone, Fabio and Radillo, Oriano and Zauli, Giorgio and Secchiero, Paola} } @article {3495, title = {Organizing national responses for rare blood disorders: the Italian experience with sickle cell disease in childhood.}, journal = {Orphanet J Rare Dis}, volume = {8}, year = {2013}, month = {2013}, pages = {169}, abstract = {

BACKGROUND: Sickle cell disease (SCD) is the most frequent hemoglobinopathy worldwide but remains a rare blood disorder in most western countries. Recommendations for standard of care have been produced in the United States, the United Kingdom and France, where this disease is relatively frequent because of earlier immigration from Africa. These recommendations have changed the clinical course of SCD but can be difficult to apply in other contexts. The Italian Association of Pediatric Hematology Oncology (AIEOP) decided to develop a common national response to the rising number of SCD patients in Italy with the following objectives: 1) to create a national working group focused on pediatric SCD, and 2) to develop tailored guidelines for the management of SCD that could be accessed and practiced by those involved in the care of children with SCD in Italy.

METHODS: Guidelines, adapted to the Italian social context and health system, were developed by 22 pediatric hematologists representing 54 AIEOP centers across Italy. The group met five times for a total of 128~hours in 22~months; documents and opinions were circulated via web.

RESULTS: Recommendations regarding the prevention and treatment of the most relevant complications of SCD in childhood adapted to the Italian context and health system were produced.

CONCLUSIONS: Creating a network of physicians involved in the day-to-day care of children with SCD is feasible in a country where it remains rare. Providing hematologists, primary and secondary care physicians, and caregivers across the country with web-based guidelines for the management of SCD tailored to the Italian context is the first step in building a sustainable response to a rare but emerging childhood blood disorder and in implementing the World Health Organization{\textquoteright}s suggestion "to design (and) implement {\textellipsis} comprehensive national integrated programs for the prevention and management of SCD".

}, keywords = {Adolescent, Anemia, Sickle Cell, Child, Child, Preschool, Disease Management, Female, Hematologic Diseases, Humans, Infant, Infant, Newborn, Italy, Male, Neonatal Screening, Rare Diseases}, issn = {1750-1172}, doi = {10.1186/1750-1172-8-169}, author = {Colombatti, Raffaella and Perrotta, Silverio and Samperi, Piera and Casale, Maddalena and Masera, Nicoletta and Palazzi, Giovanni and Sainati, Laura and Russo, Giovanna} } @article {1884, title = {Oral rehabilitation of children with ectodermal dysplasia.}, journal = {BMJ Case Rep}, volume = {2012}, year = {2012}, month = {2012}, abstract = {

The aim of this study was to describe the clinical treatment of young patients, affected by ectodermal dysplasia (ED), and to possibly establish clinical guidelines. The study design was case series. ED syndromes (EDs) are a heterogeneous group of inherited diseases characterised by abnormal development of tissues of ectodermal origin. The most common form of EDs is X linked hypohidrotic ED (HED). Characteristic triad of HED is oligo-anodontia, hypotricosis, hypo-anhydrosis. Oligo-anodontia is one of the most severe impairment, since it affects chewing, swallowing, speech, esthetics and social relation. Early prosthetic rehabilitation (at 2-3 years of age), with partial or complete dentures, is essential to improve oral function and reduce the social impairment.

}, keywords = {Child, Child, Preschool, Denture, Complete, Denture, Partial, Ectodermal Dysplasia 1, Anhidrotic, Esthetics, Dental, Humans, Male, Mastication, Speech}, issn = {1757-790X}, doi = {10.1136/bcr.01.2012.5652}, author = {Montanari, Marco and Callea, Michele and Battelli, Filippo and Piana, Gabriela} } @article {1925, title = {Oral zinc for treating diarrhoea in children.}, journal = {Cochrane Database Syst Rev}, volume = {6}, year = {2012}, month = {2012}, pages = {CD005436}, abstract = {

BACKGROUND: In developing countries, diarrhoea causes around two million child deaths annually. Zinc supplementation during acute diarrhoea is currently recommended by the World Health Organization and UNICEF.

OBJECTIVES: To evaluate oral zinc supplementation for treating children with acute or persistent diarrhoea.

SEARCH METHODS: In February 2012, we searched the Cochrane Infectious Diseases Group Specialized Register, CENTRAL (The Cochrane Library 2011, Issue 11), MEDLINE, EMBASE, LILACS, CINAHL, mRCT, and reference lists. We also contacted researchers.

SELECTION CRITERIA: Randomized controlled trials comparing oral zinc supplementation with placebo in children aged one month to five years with acute or persistent diarrhoea, including dysentery.

DATA COLLECTION AND ANALYSIS: Both authors assessed trial eligibility and risk of bias, extracted and analysed data, and drafted the review. Diarrhoea duration and severity were the primary outcomes. We summarized dichotomous outcomes using risk ratios (RR) and continuous outcomes using mean differences (MD) with 95\% confidence intervals (CI). Where appropriate, we combined data in meta-analyses (using the fixed- or random-effects model) and assessed heterogeneity.The quality of evidence has been assessed using the GRADE methods

MAIN RESULTS: Twenty-four trials, enrolling 9128 children, met our inclusion criteria. The majority of the data is from Asia, from countries at high risk of zinc deficiency, and may not be applicable elsewhere.Acute diarrhoeaThere is currently not enough evidence from well conducted randomized controlled trials to be able to say whether zinc supplementation during acute diarrhoea reduces death or hospitalization (very low quality evidence).In children aged greater than six months with acute diarrhoea, zinc supplementation may shorten the duration of diarrhoea by around 10 hours (MD -10.44 hours, 95\% CI -21.13 to 0.25; 2091 children, five trials, low quality evidence), and probably reduces the number of children whose diarrhoea persists until day seven (RR 0.73, 95\% CI 0.61 to 0.88; 3865 children, six trials, moderate quality evidence). In children with signs of moderate malnutrition the effect appears greater, reducing the duration of diarrhoea by around 27 hours (MD -26.98 hours, 95\% CI -14.62 to -39.34; 336 children, three trials, high quality evidence).Conversely, In children aged less than six months, the available evidence suggests zinc supplementation may have no effect on mean diarrhoea duration (MD 5.23 hours, 95\% CI -4.00 to 14.45; 1334 children, two trials, low quality evidence), and may even increase the proportion of children whose diarrhoea persists until day seven (RR 1.24, 95\% CI 0.99 to 1.54; 1074 children, one trial, moderate quality evidence).No trials reported serious adverse events, but zinc supplementation during acute diarrhoea causes vomiting in both age groups (RR 1.59, 95\% 1.27 to 1.99; 5189 children, 10 trials, high quality evidence).Persistent diarrhoeaIn children with persistent diarrhoea, zinc supplementation probably shortens the duration of diarrhoea by around 16 hours (MD -15.84 hours, 95\% CI -25.43 to -6.24; 529 children, five trials, moderate quality evidence).

AUTHORS{\textquoteright} CONCLUSIONS: In areas where the prevalence of zinc deficiency or the prevalence of moderate malnutrition is high, zinc may be of benefit in children aged six months or more.The current evidence does not support the use of zinc supplementation in children below six months of age.

}, keywords = {Acute Disease, Age Factors, Child, Child, Preschool, Diarrhea, Humans, Infant, Randomized Controlled Trials as Topic, Time Factors, Trace Elements, Zinc}, issn = {1469-493X}, doi = {10.1002/14651858.CD005436.pub3}, author = {Lazzerini, Marzia and Ronfani, Luca} } @article {1710, title = {Osteoprotegerin induces morphological and functional alterations in mouse pancreatic islets.}, journal = {Mol Cell Endocrinol}, volume = {331}, year = {2011}, month = {2011 Jan 1}, pages = {136-42}, abstract = {

Although serum osteoprotegerin (OPG) is significantly increased in diabetic subjects, its potential role in beta cell dysfunction has not been investigated. This study aimed to assess the effect of full-length OPG administered in vivo in mice on pancreatic islet structure and function and its interaction with the renin-angiotensin system (RAS). OPG-treated mice showed increased islet monocyte/macrophage infiltration, fibrosis and apoptosis with reduction of islet function. The remodeling of islet architecture was associated with increased pancreatic expression of components of the RAS, growth factor genes (transforming growth factor β and connective tissue growth factor) and inflammatory molecules (monocyte chemotactic protein-1 and vascular adhesion molecule type 1). Prevention of these changes with improvement of insulin secretion was observed in ramipril treated animals. Our data suggest that OPG might play an important role in promoting beta cell dysfunction and that the upregulation of the local RAS represents one possible mechanism responsible for the OPG-induced beta cell dysfunction.

}, keywords = {Animals, Apoptosis, Blood Glucose, Blood Pressure, Body Weight, Cell Lineage, Cell Movement, Chemokine CCL2, Connective Tissue Growth Factor, Fibrosis, Gene Expression Regulation, Humans, Insulin, Islets of Langerhans, Macrophages, Mice, Monocytes, Organ Size, Osteoprotegerin, Peptidyl-Dipeptidase A, Receptor, Angiotensin, Type 1, Systole, Transforming Growth Factor beta, Vascular Cell Adhesion Molecule-1}, issn = {1872-8057}, doi = {10.1016/j.mce.2010.08.019}, author = {Toffoli, Barbara and Bernardi, Stella and Candido, Riccardo and Sabato, Nicoletta and Carretta, Renzo and Corallini, Federica and Secchiero, Paola and Zauli, Giorgio and Fabris, Bruno} } @article {1784, title = {Osteoprotegerin promotes vascular fibrosis via a TGF-β1 autocrine loop.}, journal = {Atherosclerosis}, volume = {218}, year = {2011}, month = {2011 Sep}, pages = {61-8}, abstract = {

BACKGROUND: This study was designed to evaluate the potential role of osteoprotegerin (OPG) in arterial fibrosis.

METHODS: Aortic samples were analyzed after in vivo treatment of ApoE(-/-) mice with recombinant human OPG. Mouse vascular smooth muscle cells (VSMC) were exposed in vitro to recombinant OPG and analyzed for markers of inflammation and fibrosis, such as fibronectin, collagen I, III, IV and transforming growth factor-β1 (TGF-β1). Conversely, the potential modulation of endogenous OPG expression and release by VSMC was analyzed in response to different pro-atherosclerotic cytokines, TGF-β1, platelet derived growth factor (PDGF) and angiogensin II (Ang II).

RESULTS: In vivo treatment with human OPG induced signs of fibrosis and up-regulated the arterial expression of TGF-β1. Consistently, in vitro treatment of VSMC with human OPG induced the expression of fibronectin, collagen type I, III, IV, metalloprotein-2 (MMP-2) and MMP-9, as well as of TGF-β1. On the other hand, exposure to recombinant TGF-β1 promoted the expression/release of endogenous OPG and mediated the increase of OPG release induced by PDGF and Ang II in VSMC.

CONCLUSIONS: Taken together, these data support a pathogenic role for OPG in the development and progression of atherosclerotic lesions and suggest the existence of a vicious circle between TGF-β1 and OPG.

}, keywords = {Animals, Apolipoproteins E, Cell Proliferation, Collagen, Fibronectins, Fibrosis, Gene Expression Regulation, Humans, Mice, Mice, Inbred C57BL, Mice, Transgenic, Muscle, Smooth, Vascular, Myocytes, Smooth Muscle, Osteoprotegerin, Platelet-Derived Growth Factor, Transforming Growth Factor beta1}, issn = {1879-1484}, doi = {10.1016/j.atherosclerosis.2011.05.019}, author = {Toffoli, Barbara and Pickering, Raelene J and Tsorotes, Despina and Wang, Bo and Bernardi, Stella and Kantharidis, Phillip and Fabris, Bruno and Zauli, Giorgio and Secchiero, Paola and Thomas, Merlin C} } @article {1645, title = {Oxidative stress-based cytotoxicity of delphinidin and cyanidin in colon cancer cells.}, journal = {Arch Biochem Biophys}, volume = {501}, year = {2010}, month = {2010 Sep 1}, pages = {151-7}, abstract = {

Colorectal cancer is the second most frequent cause of cancer death in the western world. Although the prognosis has improved after the introduction of newer anticancer drugs, the treatment of metastatic colorectal cancer still remains a challenge due to a high percentage of drug-resistant tumor forms. We aimed at testing whether anthocyanidins exerted cytotoxicity in primary (Caco-2) and metastatic (LoVo and LoVo/ADR) colorectal cancer cell lines. Both cyanidin and delphinidin, though neither pelargonidin nor malvidin, were cytotoxic in metastatic cells only. The cell line most sensitive to anthocyanidins was the drug-resistant LoVo/ADR. There, cellular ROS accumulation, inhibition of glutathione reductase, and depletion of glutathione could be observed. This suggests that anthocyanidins may be used as sensitizing agents in metastatic colorectal cancer therapy.

}, keywords = {Anthocyanins, Antioxidants, Apoptosis, Caco-2 Cells, Camptothecin, Cell Line, Tumor, Colonic Neoplasms, Drug Resistance, Neoplasm, Glutathione, Glutathione Reductase, Humans, Oxidants, Oxidative Stress}, issn = {1096-0384}, doi = {10.1016/j.abb.2010.05.019}, author = {Cvorovic, Jovana and Tramer, Federica and Granzotto, Marilena and Candussio, Luigi and Decorti, Giuliana and Passamonti, Sabina} }